Interesting statement this IMO
Other pipeline products
Botanix continues work to finalize the clinical study report for its rosacea study with BTX 1702 and
close out activities at the various clinical sites in Australia and New Zealand, as well as complete the
data package for ethics approval for the BTX 1801 development program, following the
announcement of positive data from the Phase 2a study. The Company’s focus remains, however, on
preparing for and securing the approval of SB given the near term commercial and revenue generating
potential for that product.
In parallel Botanix continues to explore opportunities to add soon to be approved and marketed
products to its pipeline to bolster the revenue generation potential of the Company and to enhance
its attractiveness, as both a stand-alone company or an M&A target.
- Forums
- ASX - By Stock
- BOT
- BOT - Anything but charting
BOT - Anything but charting, page-4574
-
- There are more pages in this discussion • 4,697 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
|
|||||
Last
38.0¢ |
Change
0.055(16.9%) |
Mkt cap ! $687.8M |
Open | High | Low | Value | Volume |
33.0¢ | 38.0¢ | 33.0¢ | $7.103M | 19.63M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 134000 | 37.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.0¢ | 650314 | 19 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 132500 | 0.375 |
3 | 7752 | 0.370 |
2 | 24000 | 0.365 |
1 | 4166 | 0.360 |
3 | 59669 | 0.355 |
Price($) | Vol. | No. |
---|---|---|
0.380 | 502144 | 15 |
0.385 | 164500 | 4 |
0.390 | 276986 | 11 |
0.395 | 750000 | 5 |
0.400 | 660032 | 20 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |